Yuyu Pharmaceutical said Thursday that it has launched Bazestar, a compound osteoporosis treatment

Bazestar’s main ingredient bazedoxifene is a selective estrogen receptor modulator used for treating and preventing osteoporosis in postmenopausal women in Korea, Japan and some European countries. The treatment also contains recommended dose of cholecalciferol (vitamin D3), 800IU, from various osteoporosis associations.

Unlike the existing bisphosphonate medications, patients can take the drug after meals. The drug also has no orthostatic limit, which in turn will lead to high compliance.

Yuyu Pharmaceutical launched Bazestar also as the cheapest drug among the same ingredients, 555 won ($0.50) per tablet, thus minimizing the financial burden on patients with osteoporosis. To make it easier for patients to remember when to take the drug, the company has put the date of use on the back of each press through packages (PTP).

According to the National Health Insurance Service, osteoporosis patients increased 13.7 percent, from 752,618 in 2013 to 856,009 in 2017. The Korean Society for Bone and Mineral Research also said the incidence of osteoporotic fractures has been steadily increasing by 4 percent every year for patients over 50.

“As vitamin D is necessary to prevent and treat osteoporosis, Bazestar, which binds vitamin D to Bazedoxifene, is advantageous and convenient for patients as it can be taken at once,” said Hong Tae-uei, Yuyu Pharmaceutical’s ethical drug marketing head. “It is also expected that Bazestar, which shows the date of taking the pill in the PTP (press through package) form, will increase the compliance of the treatment by allowing the patient to take medication at the right time.”

Copyright © KBR Unauthorized reproduction, redistribution prohibited